Skip to main content

Our mission

We create inspired medicines that matter to cancer patients based on our expertise and ADC technologies

ADC Drug Development

We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.

ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.

News

PR: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
23 May 2024
Open
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
25 April 2024
Open
PR: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
05 April 2024
Open
PR: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
27 March 2024
Open

Meet us

  • Panel, presentation

    ASCO - American Society of Clinical Oncology - Annual Meeting

    31. Mai - 4. Juni
  • Panel, presentation

    10th Annual Oncology Innovation Forum

    31. Mai
  • BIO international Convention

    3. - 6. Juni
  • Jefferies Global Healthcare Conference

    4. - 6. Juni

    Partner Information

    TitleDate
    Telix: First Patient Dosed in Austrian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
    2 May 2024
    Read more
    Telix: First Patient Dosed in Special Access Scheme in Australia for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
    26 April 2024
    Read more
    Telix: TLX250-CDx (Zircaix®) Recognised in EAU Guidelines as an Emerging Technology for the Management of RCC (Kidney Cancer)
    12 April 2024
    Read more
    Telix: First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
    25 March 2024
    Read more